Additional within-case comparison information. by Ryan J. Treves (13527735)

“…In 1999, California introduced changes to its clean water program that modified each of these components, and in the present work we explore the impact of these changes using a mixed-methods approach. …”

POTW sample summary. by Ryan J. Treves (13527735)

“…In 1999, California introduced changes to its clean water program that modified each of these components, and in the present work we explore the impact of these changes using a mixed-methods approach. …”

Data Sheet 1_Hyperbaric oxygen therapy for radiation enteritis and clinical parameters: a systematic review and meta-analysis.docx by Yuhan Wang (595964)

“…</p>Results<p>This study analyzed data from 22 clinical studies involving 1,318 subjects, including six RCTs incorporated into a meta-analysis. Moderate-quality evidence suggested that HBOT could significantly reduce the incidence of RE [OR = 0.32, 95% CI (0.14, 0.72), P = 0.006], particularly showing a significant advantage in decreasing the incidence of grade 3 or higher RE according to the RTOG/EORTC criteria [OR = 0.37, 95% CI (0.17, 0.82), P = 0.01]. …”

Table 7_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 2_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 3_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 4_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xls by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 1_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 6_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 5_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.docx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Supplementary file 1_Effects of non-HDL-C and statin therapy on mortality in ARDS: a retrospective cohort study.docx by Haiming Hu (12451365)

“…Both univariate (HR, 0.48; 95% CI, 0.41–0.58; p < 0.001) and multivariate (HR, 0.49; 95% CI, 0.41–0.58; p < 0.001) Cox regression analyses revealed that statin therapy significantly decreased short-term mortality. Subsequent subgroup analyses further indicated that the beneficial effect of statins was more evident in patients with elevated non-HDL-C levels.…”

Image 1_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.tif by Zhengqing Yu (12641890)

“…Compared with individuals with a low level of circulating GDF-15, those with high GDF-15 level had a higher prevalence of hypertension [odds ratios (OR) 1.60, 95% confidence interval (CI) 1.37–1.88, P < 0.001). …”

Image 2_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.tif by Zhengqing Yu (12641890)

“…Compared with individuals with a low level of circulating GDF-15, those with high GDF-15 level had a higher prevalence of hypertension [odds ratios (OR) 1.60, 95% confidence interval (CI) 1.37–1.88, P < 0.001). …”

Table 1_Assessing the impact of risk perception on fisheries performance: a structural equation modeling approach in coastal fisheries.docx by Muhammad Mohsin (1335447)

“…Published literature documents such a scenario in the case of Pakistan, which results in a decreased economic contribution to the fisheries sector. …”

Table 4_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Compared with individuals with a low level of circulating GDF-15, those with high GDF-15 level had a higher prevalence of hypertension [odds ratios (OR) 1.60, 95% confidence interval (CI) 1.37–1.88, P < 0.001). …”

Table 1_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Compared with individuals with a low level of circulating GDF-15, those with high GDF-15 level had a higher prevalence of hypertension [odds ratios (OR) 1.60, 95% confidence interval (CI) 1.37–1.88, P < 0.001). …”

Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study by Masateru Tajiri (19818114)

“…NfL levels significantly decreased with patisiran, although no significant changes were observed in CMAP and SNAP.…”

Table 3_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Compared with individuals with a low level of circulating GDF-15, those with high GDF-15 level had a higher prevalence of hypertension [odds ratios (OR) 1.60, 95% confidence interval (CI) 1.37–1.88, P < 0.001). …”

Table 2_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Compared with individuals with a low level of circulating GDF-15, those with high GDF-15 level had a higher prevalence of hypertension [odds ratios (OR) 1.60, 95% confidence interval (CI) 1.37–1.88, P < 0.001). …”

Model fit indices for social isolation. by Juhee Choi (2619733)

“…The final sample included 2,395 participants (mean age = 46.32, SD = 16.47) who completed a face-to-face interview survey. …”